Biogen Inc. Common Stock
BIIB
$0.00
-3.50%
Biogen Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative and rare diseases. It is an established player with a core portfolio spanning multiple sclerosis and newer franchises in areas like Alzheimer's and spinal muscular atrophy.
BIIB
Biogen Inc. Common Stock
$0.00
Related headlines
Investment Opinion: Should I buy BIIB Today?
Synthesized Analyst Rating: HOLD. The analysis reveals a company in transition with compelling long-term growth drivers but near-term fundamental headwinds and volatility. The attractive forward P/E of 11.2 and strong analyst EPS growth projections support a bullish long-term view. However, the current price near the upper end of its 52-week range, high short interest, and inconsistent quarterly performance warrant caution, suggesting investors wait for a more attractive entry point or clearer signs of sustained execution before establishing a full position.
Sign up to view all
BIIB 12-Month Price Forecast
The investment thesis is balanced. The potential for significant earnings growth (trailing EPS $8.78 to forecast $18.14) and pipeline success is offset by near-term financial volatility and a declining revenue base. The neutral stance reflects this transition period, where the outcome is highly dependent on successful execution of new growth initiatives.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Biogen Inc. Common Stock's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
15 analysts
Implied Upside
—
vs. current price
Analyst Count
15
covering this stock
Price Range
$0 - $0
Analyst target range
Wall Street analyst coverage includes 15 firms providing estimates, with an average EPS forecast of $18.14 and average revenue forecast of $9.60 billion for the upcoming period. Recent institutional ratings show a mix of opinions, including 'Buy' from Canaccord Genuity and Guggenheim, 'Outperform' from RBC Capital, and 'Hold' or 'Neutral' ratings from firms like Citigroup and Wedbush, indicating a consensus view that is cautiously optimistic.
Bulls vs Bears: BIIB Investment Factors
Biogen presents a classic biopharma turnaround story with high risk and high potential reward. The bull case is driven by a strengthening pipeline, strategic M&A, and a cheap forward valuation. The bear case highlights fundamental instability in its core business, high short interest, and execution risks on new growth initiatives.
Bullish
- Strong Pipeline Catalysts: Recent FDA approvals for Spinraza and promising new autoimmune therapy data signal growth.
- Strategic Acquisitions for Growth: Blockbuster Apellis deal adds two fast-growing drugs, enhancing long-term portfolio.
- Solid Financial Position: Strong balance sheet with low debt (36.5% D/E) and robust free cash flow of $2.14B.
- Attractive Forward Valuation: Forward P/E of 11.2 is low, suggesting potential upside if earnings forecasts are met.
Bearish
- Revenue and Earnings Volatility: Q4 revenue declined 7.2% YoY, and net income swung to a $48.4M loss.
- Core Franchise Decline: Multiple sclerosis franchise, 40% of revenue, is described as declining.
- High Short Interest: Short ratio of 4.83 indicates significant market skepticism and potential downside pressure.
- Moderate Capital Efficiency: Trailing ROE of 7.4% and ROA of 6.1% indicate suboptimal returns on capital.
BIIB Technical Analysis
The stock has demonstrated significant volatility with a strong overall uptrend over the past six months, rising approximately 18.1% from a close of $155.25 on October 2, 2025, to $183.33 on March 31, 2026. Short-term performance shows a 4.2% gain over the last three months, though it declined 4.4% over the past month, indicating recent consolidation or pullback. The current price of $183.33 sits near the upper end of its 52-week range ($110.04 to $202.41), representing about 81% of the range's span from the low, suggesting the stock is in a relatively strong position but below its recent peak.
Beta
0.16
0.16x market volatility
Max Drawdown
-24.8%
Largest decline past year
52-Week Range
$110-$202
Price range past year
Annual Return
+35.0%
Cumulative gain past year
| Period | BIIB Return | S&P 500 |
|---|---|---|
| 1m | -3.6% | -4.3% |
| 3m | -0.3% | -4.0% |
| 6m | +10.9% | -2.0% |
| 1y | +35.0% | +22.2% |
| ytd | -0.3% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BIIB Fundamental Analysis
Revenue trends show volatility, with Q4 2025 revenue of $2.28 billion declining 7.2% year-over-year and 7.1% sequentially from Q3. Profitability has been inconsistent, as evidenced by a net loss of $48.4 million in Q4 2025 compared to a net income of $466.5 million in Q3, reflecting margin pressure. The company maintains a solid financial position with a debt-to-equity ratio of 36.5% and a strong current ratio of 2.68, supported by robust annual free cash flow of $2.14 billion. Operational efficiency metrics are mixed, with a trailing ROE of 7.4% and ROA of 6.1%, indicating moderate returns on capital employed.
Quarterly Revenue
$2.3B
2025-12
Revenue YoY Growth
-0.07%
YoY Comparison
Gross Margin
+0.78%
Latest Quarter
Free Cash Flow
$2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BIIB Overvalued?
Given the company's positive trailing net income, the primary valuation metric is the trailing P/E ratio of 20.9, based on an EPS of $8.78. This suggests the market is valuing the company at a moderate earnings multiple. For peer comparison, industry average valuation multiples are not provided in the data, so a relative assessment cannot be made.
PE
20.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -137x~38x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.6x
Enterprise Value Multiple
Investment Risk Disclosure
Biogen's primary risk is operational and financial volatility, as evidenced by a sharp Q4 2025 net loss following a profitable Q3, driven by revenue declines and high operating expenses. The company's heavy reliance on a declining multiple sclerosis franchise (40% of revenue) creates significant business model risk, despite newer drugs in Alzheimer's and SMA offering growth potential. Execution risk is heightened by the recent blockbuster Apellis acquisition, which pressures the near-term balance sheet and introduces integration challenges. Furthermore, the stock's high short interest (ratio of 4.83) and beta of 0.145, while low, indicate it can trade on idiosyncratic news, leading to potential sharp declines on pipeline setbacks or disappointing launch trajectories for key drugs like Leqembi and Spinraza.
FAQ
Key risks include: 1) Revenue and earnings volatility, as seen in the Q4 2025 net loss of $48.4M. 2) Decline of the multiple sclerosis franchise, which generates 40% of revenue. 3) Execution risk on new drug launches (Leqembi, Skyclarys) and the integration of the Apellis acquisition. 4) High short interest (ratio 4.83), which can amplify downward price moves on negative news. 5) Pipeline setbacks common in drug development.
The 12-month outlook is mixed with a base case target range of $175 to $202, representing modest upside from the current ~$183. The bull case ($202-$225) depends on successful execution of growth initiatives, while the bear case ($140-$175) reflects risks of further core business erosion. The average analyst EPS forecast of $18.14, if achieved, would be a major positive catalyst, but the stock's path will be volatile as it transitions its revenue base.
BIIB appears modestly undervalued based on forward earnings potential but fairly valued on a trailing basis. Its trailing P/E of 20.9 is reasonable, but its forward P/E of 11.2 is low, suggesting the market is discounting future earnings growth. This discount reflects risks like core business decline and acquisition integration. If the company meets its average EPS forecast of $18.14, the current price implies significant undervaluation.
BIIB is a HOLD for most investors at its current price near $183.33. While its forward P/E of 11.2 is attractive and analyst EPS forecasts project strong growth to $18.14, the stock faces near-term headwinds including revenue volatility, a declining core franchise, and high short interest. It may become a more compelling buy on a pullback or upon demonstration of sustained quarterly execution and successful new drug launches.
BIIB is primarily suitable for long-term investors with a horizon of 3-5 years who can tolerate high volatility. The company's value proposition is based on the multi-year commercialization of its new neurodegenerative disease franchises. Short-term trading is hazardous due to the stock's sensitivity to clinical trial data, FDA decisions, and quarterly earnings surprises, as evidenced by its 24.8% max drawdown in the provided data.